🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Proud to have MRE as an essential part of the new AASLD guidance on selecting MASH patients for #Resmetirom biopsy F2-F3 MASH (w/in 3 Years) or liver stiffness by VCTE 8-15kPa / MRE 3.1-4.4 kPa pubmed.ncbi.nlm.nih.gov/39422487/

Looking forward to this session at #RSNA24 Mastering MR Elastography: Enhancing Chronic Liver Disease Detection and Management featuring Kay Pepin and Sudhakar Venkatesh MD (ಸುಧಾಕರ್ ವೆಂಕಟೆೇಶ್) events.siemens-healthineers.com/sessions/vendo…

Pros and cons of current NITs in MetALD. Inflammation, excess weight, alcohol use and low specificity are the main caveats of NITs. Fantastic talk from Maja Thiele at the MetALD Conference ! #LiverTwitter Rohit Loomba Aleksander Krag EASL Education EASLnews MASLD Research Center

Join Jonathan Dillman in the RSNA Hands-On Lab: Liver Elastography session starting now! #RSNA24 #RSNA2024

Just started. Join us in Arie Crown Theater! Eric Topol is giving the Plenary Session on #AI Transformation of #Medicine. #RSNA24 #AIinMedicine RSNA

So great to be at #RSNA24!

Don't forget to join us at this Siemens Healthineers session at #RSNA24 Mastering MR Elastography: Enhancing Chronic Liver Disease Detection and Management featuring Kay Pepin and Sudhakar Venkatesh MD (ಸುಧಾಕರ್ ವೆಂಕಟೆೇಶ್) Today (Tues), 12/3, 3pm, Booth 1154 events.siemens-healthineers.com/sessions/vendo…

Kay Pepin delivered a great talk at #RSNA254 on the current state of MRI Biomarkers for novel MASLD/MASH therapy. Here's a quick summary 👇 Scott Isaacs Rohit Loomba Mazen Noureddin, MD, MHSc Alina Allen #livertwitter

Thank you to all the imaging centers and radiology practices working tirelessly to empower patients and clinicians with greater confidence in diagnosing and managing liver disease. #MASLD #MASH🙏

Great to have Luis Antonio Díaz, MD on team MASLD Research Center UCSD Gastroenterology - anyone interested in MetALD or ALD trial - check out inclusion criteria & use of Peth- AUD include MRI-PDFF/MRE in SLD trials as you build from phase 1 to 2b - AASLD EASL Education Shivaram P Singh #LiverTwitter

Interesting paper here. Couple of quick thoughts: - a bad test (low sensitivity) is the worst thing. Patients value most: "if I have the disease, I want the test to find it early" - False Positives: the data here seem odd. As the FP% decreases from 40% to 20% and then 10%, the

Super busy first day at #SAR25! A lot of interest from abdominal Radiologists on: - quantitative MRI biomarkers (MRI-PDFF and MRE) for novel MASLD/MASH therapies - Hep+ as an automated solution to MRE analysis - new MRE Flex Passive Drivers for improved patient comfort Stop by

Happy to be co-author on a great and highly practical study (lead author Yasaman Vali) from the LITMUS Consortium on the clinical factors that might require adjusted thresholds to noninvasive tests (NITs) for liver fibrosis assessment. Some key takeaways: 🟢 NITs like FIB-4,

Liver health made simple! We're crafting memorable slogans to help clinicians and patients easily identify when MRE liver stiffness readings of 3-5 kPa indicate Rezdiffra treatment. "MRE 3 to 5? Rezdiffra keeps your liver alive!" "3 to 5 on MRE? Rezdiffra is the key." "MRE

Consensus panel recs: Diagnosis and Monitoring Pathways Using Non-Invasive Tests in Patients With A1AT-liver disease #livertwitter my_UEG AASLD EASLnews American Gastroenterological Association (AGA) pubmed.ncbi.nlm.nih.gov/40072894/

MR Elastography Reveals Spatial Liver Heterogeneity in MASLD Progression  healthmanagement.org/c/it/News/mr-e…

Evaluating Diagnostic Accuracy and Cost Implications in MASLD Fibrosis Staging resoundant.com/single-post/ev…

A new study in Nature caught my attention for its innovative approach to a long-standing challenge: noninvasively assessing liver inflammation in MASH. lnkd.in/evmimxGB The team (Vanderbilt Radiology; Xiaoyu Jiang, John Gore et al) introduces MR cytometry - an imaging

19% Most imaging biomarkers try to prove they’re specific. MRE did the opposite early on - RSNA QIBA experts were working to standardize MRE for *clinical use* first - not just for clinical trials. So the widely cited 19% repeatability coefficient (RC) for MRE wasn’t